POSSIBILITIES OF USING LOW-MOLECULAR-WEIGHT HEPARIN IN THE COMPLEX TREATMENT OF WOMEN WITH TUMORS OF THE REPRODUCTIVE SYSTEM

Benign and malignant tumors of the organs of the female reproductive system are the most common diseases requiring medical and surgical treatment. They are rarely the cause of acute complications. However, the thromboembolic disease is a serious illness, sometimes causing death due to acute the pulmonary embolism. Venous thromboembolism secondary to Benign and malignant tumors of the organs of the female reproductive system should be considered in a female presenting with abdominal mass and pelvic pressure. Thromboembolic disease secondary to large tumors should be treated with anticoagulation then hysterectomy. The article presents an analysis of modern literature on optimal prevention of the pulmonary thromboembolism in patients with tumors of the female reproductive system. There are analysis data of 17 (0.7 %) cases of the pulmonary thromboembolism that occurred of 2358 gynecological and oncogynecologic patients.

1. Pai M., Leung L.K., Finlay G. Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults. Literature review current through: UpToDate May 2017.

2. Martino M.A., Borges E., Williamson E. et al. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol. 2006;107(3):666-71.

3. Nyquist P., Jichici D., Bautista C. et al. Prophylaxis of venous thrombosis in neurocritical care patients: An Executive Summary of Evidence-Based Guidelines: A Statement for Healthcare Professionals From the Neurocritical Care Society and Society of Critical Care Medicine. Crit Care Med 2017; 45:476.

4. Maynard G. Preventing hospital-acquired venous thromboembolism: a guide for effective quality improvement, 2nd ed. AHRQ Publication No. 16-0001-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2015.

5. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология 2015;9(2):52. [Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic complications. Phlebology 2015;9(2):52. (In Russia)].

6. Obi A.T., Pannucci C.J., Nackashi A. et al. Validation of the Caprini Venous Thrombo-embolism Risk Assessment Model in Critically Ill Surgical Patients. JAMA Surg. 2015; 150:941.

7. Satti M.A., Saenz C.P., Raju R. et al. Should Prophylactic Anticoagulation Be Considered with Large Uterine Leiomyoma? A Case Series and Literature Review. Case Rep Obstet Gynecol. 2016; 2016:9803250

8. Duska L.R., Garrett L., Henretta M. et al. When ‘never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. Gynecol Oncol. 2010;116, 3:374–377

9. Altinbas M., Coskun H.S., Er O. et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-71

10. Kakkar A.K., Mueller I.., Bassand J.P. et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013 May 21;8(5):e63479.

11. Klerk C.P., Smorenburg S.M., Otten H.M. et al. : The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol. 2005;23:2130–5. DOI: 10.1200/JCO.2005.03.134. PMID: 15699479.

12. Sideras K., Schaefer P.L., Okuno S.H. et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006 Jun;81(6):758-67

13. Simonneau G., Laporte S., Mismetti P. et al. A Randomized Study Comparing the Efficacy and Safety of Nadroparin 2850 IU (0.3 mL) vs. Enoxaparin 4000 IU (40 Mg) in the Prevention of Venous Thromboembolism After Colorectal Surgery for Cancer. J Thromb Haemost. 2006; 4: 1693–1700

14. Mismetti P., Laporte S., Darmon J.Y. et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001 Jul;88(7):913-30

15. Albanese C. et al. comparison of the local tolerability of two subcutaneous low molecular weight heparins: CY216 and enoxaparin. Curr.Ther .Research. 1992; 51 (3):469-75

16. Di Nisio M. et al. Randomized Trial of the Effect of the Low Molecular Weight Heparin Nadroparin on Survival in Patients With Cancer. J Clin Oncol, 2005;23:2130–35

17. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J. et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947–52.

18. Bednarek W.,Karowicz-Bilińska A., Kotarski J. Position of Experts Panel of the Polish Gynecological Society in the application of low molecular weight heparin nadroparin calcium (Fraxiparine) in obstetrics and gynecology. Ginekol Pol. 2011;82(3):230-3

19. Uno K., Homma S., Satoh T. et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007;96,2:290–295

20. Ye S., Yang J., Cao D. et al. Characteristic and Prognostic Implication of Venous Thromboembolism in Ovarian Clear Cell Carcinoma: A 12-Year Retrospective Study. 2015, PLoS ONE 10(3): e0121818.

21. Arcelus JI.,Monreal M.,Caprini JA.,Guisado JG.,Soto MJ.,Núñez MJ. et al. Clinical presentation and time-course of postoperative venous thrombo-embolism: Results from the RIETE Registry. Thromb Haemost. 2008;99:546–51.

22. Zhang L., Xiancui Liu, Yunxia Xue. Analysis of deep venous thrombosis after Gynecological surgery: A clinical study of 498 cases. Pak J Med Sci. 2015 Mar-Apr; 31(2): 453–456.

23. Worley MJ Jr.,Rauh-Hain JA.,Sandberg EM.,Muto MG. Venous thrombo-embolism prophylaxis for laparoscopic surgery: a survey of members of the Society of Gynecologic Oncology. Int J Gynecol Cancer. 2013 Jan. 23(1):208-15.

24. Piovella F., Barone M. Clinical experience of nadroparin in patients with cancer. Eur Oncol 2008;4:34–40. DOI: 10.17925/EOH.2008.04.1.34.

25. Birkmeyer N.J., Finks J.F., Carlin A.M. et al. Arch. Surg 2012;147:994–998

26. Shafiq N., Malhotra S., Pandhi P. et al. A randomized controlled clinical trial to evaluate the efficacysafety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins–enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. Pharmacol 2006, 78(3):136–43

27. Nishioka J., Goodin S. et al. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. J Oncol Pharm Pract. 2007,13(2):85–97.

28. Beckman M.G., Abe K., Barnes K., et al. Strategies and Partnerships Toward Prevention of Healthcare-Associated Venous Thromboembolism. J Hosp Med. 2016 Dec; 11(Suppl 2):S5–S7.